[go: up one dir, main page]

TW200503666A - Treatment of type 1 diabetes with pde5 inhibitors - Google Patents

Treatment of type 1 diabetes with pde5 inhibitors

Info

Publication number
TW200503666A
TW200503666A TW093107099A TW93107099A TW200503666A TW 200503666 A TW200503666 A TW 200503666A TW 093107099 A TW093107099 A TW 093107099A TW 93107099 A TW93107099 A TW 93107099A TW 200503666 A TW200503666 A TW 200503666A
Authority
TW
Taiwan
Prior art keywords
diabetes
type
treatment
pde5 inhibitors
substantial
Prior art date
Application number
TW093107099A
Other languages
Chinese (zh)
Inventor
Gillian Munro Burgess
Earl Michael Gibbs
Christopher Peter Wayman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200503666A publication Critical patent/TW200503666A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.
TW093107099A 2003-03-17 2004-03-17 Treatment of type 1 diabetes with pde5 inhibitors TW200503666A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45527703P 2003-03-17 2003-03-17

Publications (1)

Publication Number Publication Date
TW200503666A true TW200503666A (en) 2005-02-01

Family

ID=33029981

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093107099A TW200503666A (en) 2003-03-17 2004-03-17 Treatment of type 1 diabetes with pde5 inhibitors

Country Status (7)

Country Link
EP (1) EP1605925A1 (en)
JP (1) JP2006520777A (en)
BR (1) BRPI0408500A (en)
CA (1) CA2519357A1 (en)
MX (1) MXPA05009242A (en)
TW (1) TW200503666A (en)
WO (1) WO2004082667A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050234068A1 (en) * 2004-04-19 2005-10-20 Baldwin Dalton D Composition and method of decreasing renal ischemic damage
EP1909793A2 (en) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
AU2006278444A1 (en) * 2005-08-04 2007-02-15 Transform Pharmaceuticals, Inc. Novel formulations comprising fenofibrate and a statin, and related methods of treatment
BRPI0716134A2 (en) 2006-09-07 2013-09-17 Nycomed Gmbh combination treatment for diabetes mellitus
WO2008149345A2 (en) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
EP2919772B1 (en) * 2012-11-13 2019-03-27 NuSirt Sciences, Inc. Pde5 inhibitors and leucine or a leucine metabolite for use in the treatment of diabetes
EP2934540B1 (en) 2012-12-24 2023-08-02 Neurogastrx, Inc. Methods for treating gi tract disorders
CN106061940A (en) 2013-11-05 2016-10-26 本古里安大学内盖夫研究发展局 Compounds for the treatment of diabetes and its associated diseases
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
MX2017016930A (en) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Method of treatment of diabetic foot ulcers.
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6189999A (en) * 1998-10-15 2000-05-08 Bioimage A/S Specific therapeutic interventions obtained by interference with redistribution and/or targetting
KR100353014B1 (en) * 1998-11-11 2002-09-18 동아제약 주식회사 Pyrazolopyrimidinone derivatives for the treatment of impotence
DE19944161A1 (en) * 1999-09-15 2001-03-22 Bayer Ag New combination for the treatment of sexual dysfunction
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
BR0112100A (en) * 2000-06-30 2003-05-20 Pfizer Method of treatment of peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
CA2436576A1 (en) * 2001-02-02 2002-08-08 Pfizer Inc. Treatment of diabetes mellitus using vardenafil
MXPA03006310A (en) * 2001-03-16 2003-09-16 Pfizer Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors.
GB0106631D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations

Also Published As

Publication number Publication date
WO2004082667A1 (en) 2004-09-30
EP1605925A1 (en) 2005-12-21
MXPA05009242A (en) 2006-04-18
JP2006520777A (en) 2006-09-14
CA2519357A1 (en) 2004-09-30
BRPI0408500A (en) 2006-03-07

Similar Documents

Publication Publication Date Title
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
IL157821A0 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
SI1546127T1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
AU4258101A (en) Combination therapies with vascular damaging activity
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
IN2005KO00312A (en)
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
TW200639159A (en) Treatment of pain
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
PT1656131E (en) Use of betaine for treating intermittent claudication
TW200616644A (en) Medicine for prevention or treatment of diabetes
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
EP1695969A4 (en) ALPHA-AMINO ACID DERIVATIVES AND THEIR USE AS MEDICAMENTS
MXPA05004920A (en) Combination comprising a cdk inhibitor and cisplatin.
GB0313386D0 (en) Treatment of disease
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
TW200642688A (en) New use of PDE7 inhibitors
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
TW200610524A (en) Medicine for prevention or treatment of diabetes